inpefa：FDA Approves Inpefa for the Treatment of Heart Failure

FDA Approves Inpefa for the Treatment of Heart Failure

2023年5月30日—TheFoodandAdministration(FDA)hasapprovedInpefa™(sotagliflozin)toreducetheriskofcardiovascular(CV)death,hospitalizationfor ...。其他文章還包含有：「highlightsofprescribinginformation」、「INPEFAcancauseserioussideeffects」、「InpefaOral:Uses,SideEffects,Interactions」、「Inpefa:Uses,Dosage」、「INPEFATM(sotagliflozin)tablets」、「NowApproved」、「Once」、「SotagliflozinfortheTreat...

查看更多離開網站

Provide From Google

highlights of prescribing information

https://dailymed.nlm.nih.gov

INPEFA is a prescription medicine used to reduce the risk of death due to heart problems (cardiovascular death), hospitalization for heart failure, and urgent ...

Provide From Google

INPEFA can cause serious side effects

https://dailymed.nlm.nih.gov

INPEFA is a prescription medicine used to reduce the risk of death due to heart problems (cardiovascular death), hospitalization for heart failure, and urgent ...

Provide From Google

Inpefa Oral: Uses, Side Effects, Interactions

https://www.webmd.com

Sotagliflozin is used by people with heart failure or by people with type 2 diabetes, kidney disease, and other heart disease risk factors to lower the risk ...

Provide From Google

Inpefa: Uses, Dosage

https://www.drugs.com

Inpefa is an oral, once-daily tablet that contains sotagliflozin which may be used to reduce the risk of cardiovascular death, ...

Provide From Google

INPEFATM (sotagliflozin) tablets

https://www.accessdata.fda.gov

INPEFA is not indicated for glycemic control. Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also ...

Provide From Google